Intrinsic Imaging Awarded Phase II Immuno-Oncology Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Multi-year Phase II immuno-oncology trial provides imaging services and RECIST v1.1 tumor response evaluation for lung cancers.

Bolton, MA / San Antonio, TX

Bolton, MA / San Antonio, TX — March 22, 2017 — Intrinsic Imaging selected for its extensive therapeutic experience in lung cancer and operational excellence in oncology and immuno-oncology clinical trials.

Intrinsic Imaging, LLC, an FDA audited and ISO certified medical imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that it has been awarded a multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small cell lung cancer.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. In addition, Intrinsic Imaging's full-time board-certified, fellowship trained radiologists will also evaluate patients' tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criterion.

"Intrinsic Imaging was selected due to our extensive therapeutic experience and operational excellence in oncology and immuno-oncology clinical trials." said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. "With our team of 70 full-time, board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide our expertise in the assessment of non-small cell lung cancer and other lung cancers."

Intrinsic Imaging's board-certified team also includes 12 oncology focused radiologists with an extensive breadth of experience in clinical trials involving carcinomas, sarcomas, and lymphomas. The company also has significant expertise in a range of assessment criterion including, but not limited to, BIRADS, Cheson, irRECIST, Lugano, Macdonald, mRecist, PERCIST, RANO and RECIST.

Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined. Non-small cell lung cancer accounts for some 85% of lung cancer diagnoses. The five-year survival rate is low often due to most patients having advanced disease at the time of presentation. Intrinsic Imaging proudly lends its expertise on this clinical trial in an effort to help in the development of an effective treatment for lung cancer.

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 650 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210

Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com